This inter- and intra-patient heterogeneity of cancer-specific biomarkers is critical to note as there is an increasing awareness of how the low or heterogeneous expression of such markers (i.e., HER2) impacts the efficacy of targeted therapies [45]. Here, ERBB2 is linked to cancer.